MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-18-2026
Moleculin Biotech P/E Ratio 2011-2026 | MBRX
Annual P/E Ratio Moleculin Biotech
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.0734 | -0.011 | -0.385 | -0.0664 | -2.35 | -2.82 | -2.73 | -2.99 | -3.64 | -4.68 | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -0.011 | -4.68 | -1.97 |
P/E Ratio of other stocks in the Biotechnology industry
| Issuer | P/E Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-0.612 | - | 2.43 % | $ 254 M |  Germany |
 |
AgeX Therapeutics
AGE
|
-0.00095 | - | -10.17 % | $ 12.2 K |  USA |
 |
I-Mab
IMAB
|
-0.236 | - | - | $ 866 M |  China |
 |
Midatech Pharma plc
MTP
|
-14.5 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
55.7 | - | - | $ 40.3 B | USA |
 |
Biophytis SA
BPTS
|
-17.6 | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
2.49 K | - | 2.54 % | $ 160 B | France |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-3.57 | - | -1.52 % | $ 24.7 M | USA |
 |
Athira Pharma
ATHA
|
-0.0167 | - | - | $ 269 M | USA |
 |
BioNTech SE
BNTX
|
6.11 | - | - | $ 27.2 B | Germany |
 |
Институт стволовых клеток человека
ISKJ
|
38.8 | - | - | - |  Russia |
 |
Checkmate Pharmaceuticals
CMPI
|
-0.859 | - | - | $ 231 M | USA |
 |
INmune Bio
INMB
|
-0.614 | $ 1.52 | -1.3 % | $ 37.6 M | USA |
 |
Exelixis
EXEL
|
15 | $ 48.7 | 9.64 % | $ 13.2 B | USA |
 |
ACADIA Pharmaceuticals
ACAD
|
14.1 | $ 21.48 | -3.89 % | $ 3.56 B | USA |
 |
Fortress Biotech
FBIO
|
11.4 | - | - | $ 71.1 M | USA |
 |
Advaxis
ADXS
|
-0.0388 | - | -9.65 % | $ 45.9 M | USA |
 |
Esperion Therapeutics
ESPR
|
-24.7 | $ 3.15 | 1.19 % | $ 655 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-0.489 | - | - | $ 5.51 M |  Israel |
 |
Aeterna Zentaris
AEZS
|
-4.94 | - | 5.93 % | $ 314 M |  Canada |
 |
Aeglea BioTherapeutics
AGLE
|
-3.48 | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
-8.58 | - | - | $ 867 M | Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
-1.71 | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
-1.33 | - | 1.93 % | $ 17.4 M | USA |
 |
Akero Therapeutics
AKRO
|
-12.9 | - | - | $ 3.67 B | USA |
 |
Aptose Biosciences
APTO
|
-0.0913 | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
-0.146 | - | -39.0 % | $ 4.57 M | USA |
 |
Akouos
AKUS
|
-1.98 | - | 0.23 % | $ 488 M | USA |
 |
Albireo Pharma
ALBO
|
-15.8 | - | -0.23 % | $ 916 M | USA |
 |
Allakos
ALLK
|
-0.612 | - | - | $ 28.6 M | USA |
 |
AlloVir
ALVR
|
-0.189 | - | 4.14 % | $ 49.1 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
-213 | $ 24.17 | 3.2 % | $ 3.08 B | USA |
 |
Allena Pharmaceuticals
ALNA
|
-2.17 | - | 3.16 % | $ 1.9 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-0.077 | - | -11.43 % | $ 502 K | USA |
 |
Applied Molecular Transport
AMTI
|
-0.175 | - | - | $ 10.1 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-4.65 | - | - | $ 2.17 B | USA |
 |
Aileron Therapeutics
ALRN
|
-0.608 | - | 10.36 % | $ 9.8 M | USA |
 |
Applied Therapeutics
APLT
|
-4.52 | - | - | $ 8.42 M | USA |
 |
Aravive
ARAV
|
-0.791 | - | -13.39 % | $ 1.45 M | USA |
 |
Aridis Pharmaceuticals
ARDS
|
-0.136 | - | 17.91 % | $ 11.1 M | USA |
 |
CRISPR Therapeutics AG
CRSP
|
-7.54 | $ 55.08 | 5.15 % | $ 4.95 B |  Schweiz |
 |
Avenue Therapeutics
ATXI
|
-0.0467 | - | -52.27 % | $ 4.45 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
-1.12 | $ 1.7 | 3.66 % | $ 452 M | Britain |
 |
AVROBIO
AVRO
|
4.63 | - | 1083.1 % | $ 745 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-0.203 | - | - | $ 7.46 M | Israel |
 |
Завод ДИОД
DIOD
|
17.7 | - | - | - | Russia |
 |
Фармсинтез
LIFE
|
-3.81 | - | - | - | Russia |
 |
AstraZeneca PLC
AZN
|
706 | - | - | $ 96.9 B | Britain |
 |
Galapagos NV
GLPG
|
-42.8 | $ 28.81 | 1.48 % | $ 2.69 B |  Belgium |
 |
Genmab A/S
GMAB
|
33.2 | $ 27.89 | 1.34 % | $ 17.2 B |  Danmark |